miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells

The relapse and resistance to cytarabine (Ara-C) therapy is still a dominating obstacle to the successful clinical treatment of acute myeloid leukemia (AML). Recent studies have shown that dysregulation of miRNAs might modulate the resistance of cancer cells to anticancer drugs; yet, the mechanism i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kankan, Chen, Yue, Chen, Zhi, Shi, Yuye, He, Zhengmei, Ding, Banghe, Wang, Chunling, Yu, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975600/
https://www.ncbi.nlm.nih.gov/pubmed/29872325
http://dx.doi.org/10.2147/OTT.S143465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975600/
https://www.ncbi.nlm.nih.gov/pubmed/29872325
http://dx.doi.org/10.2147/OTT.S143465

Ejemplares similares